Welcome!
To use the personalized features of this site, please log in or register.
If you have forgotten your username or password, we can help.
|
 |
Prognostic Factors for Survival in Patients with Epithelioid Sarcoma: 441 Cases from the SEER Database
| |
|
Original Article
Prognostic Factors for Survival in Patients with Epithelioid Sarcoma: 441 Cases from the SEER Database
Muhammad Umar Jawad1, Jason Extein2, Elijah S. Min3 and Sean P. Scully1 
| (1) |
Department of Orthopaedics, University of Miami Miller School of Medicine, University of Miami Hospital, 4th Floor, 1400 NW, 12th Avenue, Miami, FL 33136, USA |
| (2) |
Department of Surgery, Weill Cornell Medical College, New York, NY, USA |
| (3) |
Ross University School of Medicine, North Brunswick, NJ, USA |
Received: 26 September 2008 Accepted: 26 January 2009 Published online: 18 February 2009
Abstract Current stratification of prognosis in patients with epithelioid sarcoma (ES) is based largely on data reported by individual
centers with a limited number of patients. We sought to identify the important prognostic parameters using the Surveillance,
Epidemiology, and End Results (SEER) database. We identified 441 patients with ES in the database and extracted information
regarding patient demographics and clinical characteristics. Kaplan-Meier, log-rank, and Cox regression were used for analysis.
Disease-specific survival declined until 100 months after diagnosis after which survival was unrelated to epithelioid sarcoma.
The overall incidence of ES during 2005 was 0.041 per 100,000. The reported incidence has increased since 1973, with an annual
percentage change of 5.217%. On multivariate analysis, only age younger than 16 years, local stage of disease, or negative
nodes and surgical resection of the tumor predicted better disease-specific survival. We observed no increase in survival
by comparing decades of diagnosis since 1986. The SEER database shows only age younger than 16 years, negative nodes, or local
stage of disease and operability of primary disease independently predict survival in patients with ES.
Level of Evidence: Level II, prognostic study. See Guidelines for Authors for a complete description of levels of evidence.
Each author certifies that he or she has no commercial associations (eg, consultancies, stock ownership, equity interest,
patent/licensing arrangements, etc) that might pose a conflict of interest in connection with the submitted article.
Each author certifies that his or her institution has approved or does not require approval for the protocol for this investigation
and that all investigations were conducted in conformity with ethical principles of research.
References
| 1. |
American Joint Committee on Cancer. AJCC Cancer Staging Manual. 6th ed. New York, NY: Springer; 2003.
|
| |
| 2. |
Bach PB, Guadagnoli E, Schrag D, Schussler N, Warren JL. Patient demographic and socioeconomic characteristics in the SEER-Medicare
database applications and limitations. Med Care. 2002;40(8 suppl):IV-19–25.
|
| |
| 3. |
Baratti D, Pennacchioli E, Casali PG, Bertulli R, Lozza L, Olmi P, Collini P, Radaelli S, Fiore M, Gronchi A. Epithelioid
sarcoma: prognostic factors and survival in a series of patients treated at a single institution. Ann Surg Oncol. 2007;14:3542–3551.
|
| |
| 4. |
Bliss BO, Reed RJ. Large cell sarcomas of tendon sheath. Am J Clin Pathol. 1968;49:776–781.
|
| |
| 5. |
Bos GD, Pritchard DJ, Reiman HM, Dobyns JH, Ilstrup DM, Landon GC. Epithelioid sarcoma: an analysis of fifty-one cases. J Bone Joint Surg Am. 1988;70:862–870.
|
| |
| 6. |
Callister MD, Ballo MT, Pisters PW, Patel SR, Feig BW, Pollock RE, Benjamin RS, Zagars GK. Epithelioid sarcoma: results of
conservative surgery and radiotherapy. Int J Radiat Oncol Biol Phys. 2001;51:384–391.
|
| |
| 7. |
Casanova M, Ferrari A, Collini P, Bisogno G, Alaggio R, Cecchetto G, Gronchi A, Meazza C, Garaventa A, Di Cataldo A, Carli
M. Epithelioid sarcoma in children and adolescents: a report from the Italian Soft Tissue Sarcoma Committee. Cancer. 2006;106:708–717.
|
| |
| 8. |
Chase DR, Enzinger FM. Epithelioid sarcoma: diagnosis, prognostic indicators, and treatment. Am J Surg Pathol. 1985;9:241–263.
|
| |
| 9. |
Cheung MC, Perez EA, Molina MA, Jin X, Gutierrez JC, Franceschi D, Livingstone AS, Koniaris LG. Defining the role of surgery
for primary gastrointestinal tract melanoma. J Gastrointest Surg. 2008;12:731–738.
|
| |
| 10. |
Cooper GS, Virnig B, Klabunde CN, Schussler N, Freeman J, Warren JL. Use of SEER-Medicare data for measuring cancer surgery.
Med Care. 2002;40(8 suppl):IV-43–48.
|
| |
| 11. |
de Visscher SA, van Ginkel RJ, Wobbes T, Veth RP, Ten Heuvel SE, Suurmeijer AJ, Hoekstra HJ. Epithelioid sarcoma: still an
only surgically curable disease. Cancer. 2006;107:606–612.
|
| |
| 12. |
Earle CC, Nattinger AB, Potosky AL, Lang K, Mallick R, Berger M, Warren JL. Identifying cancer relapse using SEER-Medicare
data. Med Care. 2002;40(8 suppl):IV-75–81.
|
| |
| 13. |
Evans HL, Baer SC. Epithelioid sarcoma: a clinicopathologic and prognostic study of 26 cases. Semin Diagn Pathol. 1993;10:286–291.
|
| |
| 14. |
Fong Y, Coit DG, Woodruff JM, Brennan MF. Lymph node metastasis from soft tissue sarcoma in adults: analysis of data from
a prospective database of 1772 sarcoma patients. Ann Surg. 1993;217:72–77.
|
| |
| 15. |
Gloeckler Ries LA, Reichman ME, Lewis DR, Hankey BF, Edwards BK. Cancer survival and incidence from the Surveillance, Epidemiology,
and End Results (SEER) program. Oncologist. 2003;8:541–552.
|
| |
| 16. |
Gross E, Rao BN, Pappo A, Bowman L, Shearer P, Kaste S, Greenwald C, Michalkiewicz E, Pratt C. Epithelioid sarcoma in children.
J Pediatr Surg. 1996;31:1663–1665.
|
| |
| 17. |
Gutierrez JC, De Oliveira LO, Perez EA, Rocha-Lima C, Livingstone AS, Koniaris LG. Optimizing diagnosis, staging, and management
of gastrointestinal stromal tumors. J Am Coll Surg. 2007;205:479–491 (Quiz 524).
|
| |
| 18. |
Gutierrez JC, Fischer AC, Sola JE, Perez EA, Koniaris LG. Markedly improving survival of neuroblastoma: a 30-year analysis
of 1,646 patients. Pediatr Surg Int. 2007;23:637–646.
|
| |
| 19. |
Gutierrez JC, Franceschi D, Koniaris LG. How many lymph nodes properly stage a periampullary malignancy? J Gastrointest Surg. 2008;12:77–85.
|
| |
| 20. |
Gutierrez JC, Perez EA, Franceschi D, Moffat FL Jr, Livingstone AS, Koniaris LG. Outcomes for soft-tissue sarcoma in 8249
cases from a large state cancer registry. J Surg Res. 2007;141:105–114.
|
| |
| 21. |
Halling AC, Wollan PC, Pritchard DJ, Vlasak R, Nascimento AG. Epithelioid sarcoma: a clinicopathologic review of 55 cases.
Mayo Clin Proc. 1996;71:636–642.
|
| |
| 22. |
Hayat MJ, Howlader N, Reichman ME, Edwards BK. Cancer statistics, trends, and multiple primary cancer analyses from the Surveillance,
Epidemiology, and End Results (SEER) Program. Oncologist. 2007;12:20–37.
|
| |
| 23. |
Herr MJ, Harmsen WS, Amadio PC, Scully SP. Epithelioid sarcoma of the hand. Clin Orthop Relat Res. 2005;431:193–200.
|
| |
| 24. |
Hodgson N, Koniaris LG, Livingstone AS, Franceschi D. Gastric carcinoids: a temporal increase with proton pump introduction.
Surg Endosc. 2005;19:1610–1612.
|
| |
| 25. |
International Agency for Research on Cancer. International Classification of Diseases for Oncology. 3rd ed. Geneva, Switzerland: World Health Organization; 2000.
|
| |
| 26. |
Lee DJ, Voti L, Mackinnon J, Koniaris LG, Fleming LE, Huang Y, Wohler B, Franceschi D, Dietz NA, Sherman R, Soler-Vila H.
Gender- and race-specific comparison of tobacco-associated cancer incidence trends in Florida with SEER regional cancer incidence
data. Cancer Causes Control. 2008;19:711–723.
|
| |
| 27. |
Livi L, Shah N, Paiar F, Fisher C, Judson I, Moskovic E, Thomas M, Harmer C. Treatment of epithelioid sarcoma at the Royal
Marsden Hospital. Sarcoma. 2003;7:149–152.
|
| |
| 28. |
Matsushita Y, Ahmed AR, Kawaguchi N, Matsumoto S, Manabe J. Epithelioid sarcoma of the extremities: a dismal long-term outcome.
J Orthop Sci. 2002;7:462–466.
|
| |
| 29. |
Merrill RM, Dearden KA. How representative are the surveillance, epidemiology, and end results (SEER) program cancer data
of the United States? Cancer Causes Control. 2004;15:1027–1034.
|
| |
| 30. |
National Cancer Institute. Available at: http://seer.cancer.gov/csr/1975_2005/index.html. Accessed December 1, 2008.
|
| |
| 31. |
Perez EA, Gutierrez JC, Jin X, Lee DJ, Rocha-Lima C, Livingstone AS, Franceschi D, Koniaris LG. Surgical outcomes of gastrointestinal
sarcoma including gastrointestinal stromal tumors: a population-based examination. J Gastrointest Surg. 2007;11:114–125.
|
| |
| 32. |
Perez EA, Livingstone AS, Franceschi D, Rocha-Lima C, Lee DJ, Hodgson N, Jorda M, Koniaris LG. Current incidence and outcomes
of gastrointestinal mesenchymal tumors including gastrointestinal stromal tumors. J Am Coll Surg. 2006;202:623–629.
|
| |
| 33. |
Petrelli NJ. SEER data: it can be thought provoking, but where do we go from here? Ann Surg Oncol. 2007;14:2173–2174.
|
| |
| 34. |
Potosky AL, Warren JL, Riedel ER, Klabunde CN, Earle CC, Begg CB. Measuring complications of cancer treatment using the SEER-Medicare
data. Med Care. 2002;40(8 suppl):IV-62–68.
|
| |
| 35. |
Prat J, Woodruff JM, Marcove RC. Epithelioid sarcoma: an analysis of 22 cases indicating the prognostic significance of vascular
invasion and regional lymph node metastasis. Cancer. 1978;41:1472–1487.
|
| |
| 36. |
Ross HM, Lewis JJ, Woodruff JM, Brennan MF. Epithelioid sarcoma: clinical behavior and prognostic factors of survival. Ann Surg Oncol. 1997;4:491–495.
|
| |
| 37. |
Schrag D, Bach PB, Dahlman C, Warren JL. Identifying and measuring hospital characteristics using the SEER-Medicare data and
other claims-based sources. Med Care. 2002;40(8 suppl):IV-96–103.
|
| |
| 38. |
Shwartz M, Pliskin JS, Grondahl HG, Boffa J. Use of the Kaplan-Meier estimate to reduce biases in estimating the rate of caries
progression. Community Dent Oral Epidemiol. 1984;12:103–108.
|
| |
| 39. |
Spillane AJ, Thomas JM, Fisher C. Epithelioid sarcoma: the clinicopathological complexities of this rare soft tissue sarcoma.
Ann Surg Oncol. 2000;7:218–225.
|
| |
| 40. |
Virnig BA, Warren JL, Cooper GS, Klabunde CN, Schussler N, Freeman J. Studying radiation therapy using SEER-Medicare-linked
data. Med Care. 2002;40(8 suppl):IV-49–54.
|
| |
| 41. |
Warren JL, Harlan LC, Fahey A, Virnig BA, Freeman JL, Klabunde CN, Cooper GS, Knopf KB. Utility of the SEER-Medicare data
to identify chemotherapy use. Med Care. 2002;40(8 suppl):IV-55–61.
|
| |
| 42. |
Warren JL, Klabunde CN, Schrag D, Bach PB, Riley GF. Overview of the SEER-Medicare data: content, research applications, and
generalizability to the United States elderly population. Med Care. 2002;40(8 suppl):IV-3–18.
|
| |
| 43. |
Wingo PA, Jamison PM, Hiatt RA, Weir HK, Gargiullo PM, Hutton M, Lee NC, Hall HI. Building the infrastructure for nationwide
cancer surveillance and control: a comparison between the National Program of Cancer Registries (NPCR) and the Surveillance,
Epidemiology, and End Results (SEER) Program (United States). Cancer Causes Control. 2003;14:175-193.
|
| |
| 44. |
Wolf PS, Flum DR, Tanas MR, Rubin BP, Mann GN. Epithelioid sarcoma: the University of Washington experience. Am J Surg. 2008;196:407–412.
|
| |
|
|
|
|
|
|